atorvastatin has been researched along with Lupus Erythematosus, Systemic in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (40.74) | 29.6817 |
| 2010's | 11 (40.74) | 24.3611 |
| 2020's | 5 (18.52) | 2.80 |
| Authors | Studies |
|---|---|
| Li, J; Liu, X; Sun, Y; Yu, W; Yuan, L | 2 |
| Cao, C; Sun, J; Tan, Y; Wu, H; Wu, Z; Xu, W; Yu, J; Zhu, M | 1 |
| Arain, HA; Carsons, SE; DeLeon, J; Kasselman, LJ; Petri, M; Reiss, AB; Renna, HA; Voloshyna, I; Zhen, J | 1 |
| Cestari, RN; de Oliveira, RDR; de Souza, FFL; Donadi, EA; Lanchote, VL; Nardotto, GHB; Pippa, LF; Rocha, A | 1 |
| Barkoudah, E; Klein, JP; Mueller, AA; Tarter, LL; Vaidya, A | 1 |
| Ardoin, SP; Barnhart, HX; Bowyer, SL; Brunner, HI; Eberhard, A; Evans, GW; Higgins, GC; Ilowite, NT; Imundo, LF; Jung, L; Kimura, Y; Klein-Gitelman, M; Levy, D; McCurdy, DK; Mieszkalski, KL; Punaro, L; Reed, AM; Sandborg, CI; Schanberg, LE; Sherry, DD; Silver, RM; Silverman, E; Singer, NG; Soep, JB; Thompson, SD; von Scheven, E; Wagner-Weiner, L; Wallace, C; Yow, E | 1 |
| Farajzadegan, Z; Fatemi, A; Kazemi, M; Moosavi, M; Sayedbonakdar, Z; Smiley, A | 1 |
| Castañeda, A; Castejon, R; Jimenez-Ortiz, C; Mellor-Pita, S; Sollet, A; Tutor-Ureta, P; Yebra-Bango, M | 1 |
| Graham, KL; Higgins, JP; Ho, PP; Lee, LY; Steinman, L; Utz, PJ | 1 |
| Ferringer, T; Lountzis, NI; Puri, PK; Tyler, W | 1 |
| Ferreira, GA; Sato, EI; Teixeira, AL | 1 |
| Christopher-Stine, L; Kiani, AN; Magder, LS; Petri, MA; Post, W | 1 |
| Dziedzic, H; Gryga, K; Konieczynska, M; Musial, J; Plazak, W; Podolec, P; Tomkiewicz-Pajak, L | 1 |
| Kiani, AN; Magder, LS; Petri, M; Post, WS | 1 |
| Gabriel, CL; Kastelein, JJ; Major, AS; Mendez-Fernandez, YV; Stroes, ES; Tak, PP; van Leuven, SI; Wade, NS; Wilhelm, AJ | 1 |
| Ravelli, A | 1 |
| Ardoin, SP; Barnhart, HX; Bowyer, SL; Brunner, HI; Eberhard, A; Evans, GW; Higgins, GC; Ilowite, NT; Imundo, LF; Jung, L; Kimura, Y; Klein-Gitelman, M; McCurdy, D; Mieszkalski, KL; Provenzale, J; Punaro, M; Reed, AM; Sandborg, C; Schanberg, LE; Sherry, DD; Silver, R; Silverman, E; Singer, NG; Soep, JB; Thompson, SD; von Scheven, E; Wagner-Weiner, L; Wallace, C; Yow, E | 1 |
| Erhart, KH; Graziadei, IW; Obermoser, GE; Sepp, NT; Vogel, W | 1 |
| Abud-Mendoza, C; Baranda, L; Cruz-Rizo, J; Cuevas-Orta, E; de la Fuente, H; González-Amaro, R | 1 |
| Belmont, HM; Lydon, E | 1 |
| Cairns, T; Cook, HT; Elliot, V | 1 |
| Ehrenstein, MR; Isenberg, DA; Jury, EC; Mauri, C | 1 |
| Andrade, LE; Ferreira, GA; Navarro, TP; Sato, EI; Telles, RW | 1 |
| Bielinska, A; Gluszko, P | 1 |
| Kotyla, PJ | 1 |
| Hidalgo, C; Jaimez, L; Jiménez-Alonso, J; Leon, L; Sabio, JM | 1 |
1 review(s) available for atorvastatin and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
[Statins--are they potentially useful in rheumatology?].
Topics: Arthritis, Rheumatoid; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Osteoporosis; Pyrroles; Rheumatic Diseases; Simvastatin; Treatment Outcome | 2007 |
11 trial(s) available for atorvastatin and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin.
Topics: Adolescent; Adult; Area Under Curve; Atorvastatin; Case-Control Studies; Chemokine CCL2; Cytochrome P-450 CYP3A; Female; Healthy Volunteers; Humans; Interleukin-10; Liver-Specific Organic Anion Transporter 1; Lupus Erythematosus, Systemic; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Severity of Illness Index; Signal Transduction; Tumor Necrosis Factor-alpha; Young Adult | 2020 |
Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein.
Topics: Adolescent; Age Factors; Atherosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Carotid Arteries; Carotid Intima-Media Thickness; Cholesterol, LDL; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Male; Prospective Studies; Puberty; Pyrroles; Treatment Outcome | 2014 |
Atorvastatin effect on systemic lupus erythematosus disease activity: a double-blind randomized clinical trial.
Topics: Adult; Antirheumatic Agents; Atorvastatin; Blood Sedimentation; C-Reactive Protein; Double-Blind Method; Female; Heptanoic Acids; Humans; Lipids; Lupus Erythematosus, Systemic; Male; Middle Aged; Pyrroles; Severity of Illness Index; Treatment Outcome | 2014 |
Atorvastatin therapy reduces interferon-regulated chemokine CXCL9 plasma levels in patients with systemic lupus erythematosus.
Topics: Adult; Atorvastatin; Chemokine CXCL9; Chemokines; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferons; Lupus Erythematosus, Systemic; Pyrroles; Severity of Illness Index | 2010 |
Lupus Atherosclerosis Prevention Study (LAPS).
Topics: Adolescent; Adult; Aged; Atherosclerosis; Atorvastatin; Carotid Artery Diseases; Coronary Artery Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Male; Middle Aged; Pyrroles; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography; Young Adult | 2011 |
Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study.
Topics: Adult; Aged; Atorvastatin; Calcinosis; Coronary Artery Disease; Coronary Vessels; Double-Blind Method; Female; Heart; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Male; Middle Aged; Multimodal Imaging; Myocardial Perfusion Imaging; Myocardium; Positron-Emission Tomography; Prospective Studies; Pyrroles; Tomography, X-Ray Computed; Young Adult | 2011 |
Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus.
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Calcium; Carotid Artery Diseases; Carotid Intima-Media Thickness; Comorbidity; Coronary Vessels; Disease Progression; Female; Heptanoic Acids; Humans; Lupus Erythematosus, Systemic; Male; Maryland; Pyrroles | 2011 |
Use of atorvastatin in systemic lupus erythematosus in children and adolescents.
Topics: Adolescent; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Intima-Media Thickness; Child; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Lipids; Lupus Erythematosus, Systemic; Male; Pyrroles; Treatment Outcome; Young Adult | 2012 |
Therapy with statins in patients with refractory rheumatic diseases: a preliminary study.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Atorvastatin; Biomarkers; Blood Sedimentation; C-Reactive Protein; Child; Chloroquine; Dose-Response Relationship, Drug; Granulomatosis with Polyangiitis; Heptanoic Acids; HLA-DR Antigens; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes, Mononuclear; Lupus Erythematosus, Systemic; Middle Aged; Proteinuria; Pyrroles; Rheumatic Diseases; Rheumatic Fever; Simvastatin; Treatment Outcome | 2003 |
Avascular necrosis prevention with lipitor in lupus erythematosus.
Topics: Anticholesteremic Agents; Atorvastatin; Double-Blind Method; Heptanoic Acids; Humans; Lupus Erythematosus, Systemic; Osteonecrosis; Pyrroles | 2005 |
Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial.
Topics: Adult; Atorvastatin; Brachial Artery; Coronary Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Pyrroles; Risk Factors; Severity of Illness Index; Ultrasonography; Vasodilation | 2007 |
15 other study(ies) available for atorvastatin and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Effects of atorvastatin and Zishen Qingqi granules on immune function and liver function of patients with systemic lupus erythematosus with mild and moderate activity.
Topics: Adult; Atorvastatin; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lupus Erythematosus, Systemic; Male; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult | 2021 |
Effects of atorvastatin and Zishen Qingqi granules on immune function and liver function of patients with systemic lupus erythematosus with mild and moderate activity.
Topics: Atorvastatin; Humans; Immunity; Liver; Lupus Erythematosus, Systemic; Retrospective Studies; Syndrome | 2022 |
Immunomodulatory effects of atorvastatin on MRL/lpr mice.
Topics: Animals; Atorvastatin; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Mice; Mice, Inbred MRL lpr | 2022 |
Human Lupus Plasma Pro-Atherogenic Effects on Cultured Macrophages Are Not Mitigated by Statin Therapy: A Mechanistic LAPS Substudy.
Topics: Adult; Atherosclerosis; Atorvastatin; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Cholesterol; Disease Progression; Female; Gene Expression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Liver X Receptors; Lupus Erythematosus, Systemic; Macrophages; Male; Mixed Function Oxygenases; Plasma; PPAR gamma; RNA, Messenger | 2019 |
Caught in a Flare.
Topics: Arthralgia; Aspirin; Atorvastatin; Brain; Diagnosis, Differential; Exanthema; Fatigue; Female; Hematologic Tests; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Magnetic Resonance Imaging; Nervous System Diseases; Platelet Aggregation Inhibitors; Secondary Prevention; Stroke; Young Adult | 2020 |
Short-term atorvastatin therapy improves arterial stiffness of middle-aged systemic lupus erythematosus patients with pathological pulse wave velocity.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Drug Administration Schedule; Female; Humans; Lupus Erythematosus, Systemic; Middle Aged; Pulse Wave Analysis; Treatment Outcome; Vascular Stiffness; Young Adult | 2017 |
Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus.
Topics: Administration, Oral; Animals; Antibodies, Antinuclear; Atorvastatin; Cell Proliferation; Cholesterol; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-4; Lupus Erythematosus, Systemic; Mice; Mice, Inbred NZB; Pyrroles; T-Lymphocytes; Treatment Outcome | 2008 |
Hydroxychloroquine-induced hyperpigmentation: the staining pattern.
Topics: Aged; Antacids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin; Atorvastatin; Calcium Carbonate; Cardiomyopathy, Restrictive; Citalopram; Connective Tissue Diseases; Diuretics; Female; Furosemide; Glucosamine; Heptanoic Acids; Humans; Hydroxychloroquine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperpigmentation; Lupus Erythematosus, Systemic; Magnesium; Metolazone; Middle Aged; Naproxen; Omeprazole; Potassium Chloride; Prednisone; Pyrroles; Selective Serotonin Reuptake Inhibitors; Spironolactone | 2008 |
Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(-/-) mice.
Topics: Animals; Atherosclerosis; Atorvastatin; CD4-Positive T-Lymphocytes; Cholesterol; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunity, Cellular; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Mice; Mice, Inbred C57BL; Mycophenolic Acid; Pyrroles | 2012 |
Should children and adolescents with systemic lupus erythematosus be given statin therapy to prevent early atherosclerosis?
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Female; Heptanoic Acids; Humans; Lupus Erythematosus, Systemic; Male; Pyrroles | 2012 |
Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis.
Topics: Anticholesteremic Agents; Atorvastatin; Female; Hepatitis, Autoimmune; Heptanoic Acids; Humans; Immunosuppressive Agents; Liver; Liver Failure; Lupus Erythematosus, Systemic; Middle Aged; Pyrroles | 2003 |
Evolution of lesions over 10 years in a patient with SLE: flowchart approach to the new International Society of Nephrology (ISN)/Renal Pathology Society (RPS) classification of lupus nephritis.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Biopsy, Needle; Disease Progression; Follow-Up Studies; Hematuria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunoglobulin A; Immunoglobulin M; Immunosuppressive Agents; Kidney Glomerulus; Lupus Erythematosus, Systemic; Lupus Nephritis; Male; Organelles; Plasma Exchange; Pyrroles; Sclerosis; Severity of Illness Index; Software Design | 2006 |
Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cells, Cultured; Enzyme Activation; Female; G(M1) Ganglioside; Heptanoic Acids; Humans; Intracellular Fluid; Kinetics; Lupus Erythematosus, Systemic; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Male; Membrane Microdomains; Middle Aged; Protein Prenylation; Pyrroles; Receptors, Antigen, T-Cell; Signal Transduction; T-Lymphocyte Subsets | 2006 |
Comment on: Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 week controlled trial.
Topics: Atorvastatin; Controlled Clinical Trials as Topic; Endothelium, Vascular; Female; Follow-Up Studies; Heptanoic Acids; Humans; Lupus Erythematosus, Systemic; Male; Pyrroles; Treatment Outcome; Vasodilation | 2008 |
Atorvastatin-induced reversible positive antinuclear antibodies.
Topics: Adult; Antibodies, Antinuclear; Atorvastatin; Autoimmune Diseases; Heptanoic Acids; Histones; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Male; Pyrroles | 2002 |